The total number of records retrieved from this search are 16. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_3466	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration25 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3467	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration50 MOI	In-vitro result80% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3468	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result70% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3469	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (4 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result50% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3470	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration25 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3471	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration50 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3472	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result62% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3473	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (4 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result42% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3474	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration25 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3475	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration50 MOI	In-vitro result65% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3476	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result52% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3477	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (4 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3478	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration25 MOI	In-vitro result65% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3479	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration50 MOI	In-vitro result60% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3480	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result55% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3481	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin (4 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineH292	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result40% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457